Candid Therapeutics Announces Merger With Rallybio Corporation, Concurrent Private Financing of $505+ Million
Cooley advised Candid Therapeutics (Candid), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases, on its definitive merger agreement with Rallybio Corporation (Nasdaq: RLYB). Upon completion of the merger, the combined company expects to operate under the name Candid Therapeutics, Inc. and trade […]
35Pharma Enters Agreement to Be Acquired by GSK
Cooley advised 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company that specializes in developing novel protein-based therapeutics, on its agreement to sell to GSK, a global biopharma company, for $950 million. 35Pharma Enters Agreement to Be Acquired by GSK
IQM Announces Merger With Real Asset Acquisition Corp., Concurrent PIPE Financing
Cooley advised IQM Finland, a global leader in full-stack superconducting quantum computers, on its definitive business combination agreement with Real Asset Acquisition Corp. (Nasdaq: RAAQ, RAAQ), a special purpose acquisition company, which will result in IQM becoming a public company and listing American depositary shares on one of the two […]
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics
Cooley advised Faeth Therapeutics (Faeth), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling, on its acquisition by Sensei Biotherapeutics. This acquisition brings Faeth’s lead asset, PIKTOR – a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through […]
Grab Acquires Stash
Cooley advised Stash Financial, a US digital financial services company, on its definitive agreement in which Grab Holdings Limited will acquire 100% of the equity interest in Stash, with the payment for 50.1% equity interest to be made at closing at an enterprise value of US$425 million and payments for […]
Quantum Leap Acquires Veros Technologies
Cooley advised Veros Technologies, a Razor’s Edge portfolio company and a premier provider of multidomain cyber and technical operations, as well as mission-tailored communications solutions, to the US Intelligence Community and Department of Defense, on its sale to Quantum Leap, a Carlyle portfolio company and a leading, high-growth provider of […]
MARI Acquires Majority Stake in Bucket Listers
Cooley advised Bucket Listers, a leading platform for discovering live events and experiences across 20 US cities, on its majority stake acquisition by MARI, a live events and experiences holding company launched by Ari Emanuel and Mark Shapiro. MARI Acquires Majority Stake in Bucket Listers
Spring Health’s Acquisition of Alma
Cooley advised Spring Health, a top global mental health platform for employers and health plans, on its agreement to acquire Alma, a membership-based platform that helps independent mental health clinicians accept insurance and build thriving private practices. Spring Health’s Acquisition of Alma
Clorox Announces $2.25 Billion Acquisition of GOJO Industries, Makers of Purell
Cooley advised The Clorox Company (NYSE: CLX), a company that champions people to be well and thrive every single day, on its definitive agreement to acquire GOJO Industries, a leader of skin health and hygiene solutions, for $2.25 billion in cash, including anticipated tax benefits valued at approximately $330 million […]
Yelp Announces Acquisition of Hatch
Cooley advised Yelp (NYSE: YELP), the company that connects people with great local businesses, on its agreement to acquire Hatch, a top artificial intelligence-powered lead management and communication platform. Under the terms of the agreement, Yelp will acquire Hatch for approximately $270 million in cash subject to customary adjustments. Yelp […]